Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)

Completed

Conditions studied: Pulmonary Arterial Hypertension

In brief

Assess tolerability, transition methods and clinical effects of transition from sildenafil (Revatio) to tadalafil (Adcirca) for treatment of pulmonary arterial hypertension.

Key facts

Study ID

NCT01043627

Run by

Mayo Clinic

People needed

100

Starts

2009-12-01

Expected to finish

2011-12-01

Last updated by the study team

2012-11-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Treatment for PAH with sildenafil at a dose of 20mg tid or greater for at least 30 days
• Clinical decision to convert from sildenafil to tadalafil therapy
• Patient consents to study participation (for patients who have already transitioned from sildenafil to tadalafil therapy prior to study initiation or identification of the patient, if the patient has provided consent for use of their medical record for research, retrospective review of the transition process will be performed. When possible, these patients will be approached about prospective data collection for the study if the transition occurred less than 3 months prior to consideration of prospective study participation)

You may not qualify if…

• Non-group I PAH
• Age less than 18

Where it is running

• Robert Bourge MD — Birmingham, Alabama, United States
• Ron Oudiz — Torrance, California, United States
• Charles Burger MD — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.